Perspective Therapeutics Inc. has released its first quarter 2025 financial results, reporting a net loss of $18.2 million, compared to a net loss of $12.3 million in the same period of 2024. The company's total operating expenses increased by approximately 66%, reaching $22.2 million for the quarter ended March 31, 2025, up from $13.3 million in the previous year. Research and development expenses rose significantly to $14.3 million, an increase of around 92% from $7.5 million in the first quarter of 2024. This increase supports the clinical trials for the company's development assets, manufacturing, and discovery efforts. Management anticipates further increases in R&D expenses as they continue investing in novel radiopharmaceuticals and expand manufacturing capabilities. General and administrative expenses also saw an increase, reaching $7.8 million for the quarter, up from $5.9 million in the same period of 2024, primarily due to higher personnel costs. On the operational front, Perspective Therapeutics continues to progress in its clinical trials. Enrollment for VMT-α-NET, targeting neuroendocrine tumors, saw 40 patients enrolled in Cohort 2 of the Phase 1/2a trial by the end of April 2025. Additionally, the first patient was treated at a new monotherapy dose level for VMT01 in April 2025. The company also shared that its first clinical update was accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting.